Metronidazol Vioser (Metronidazole)

Metronidazole is taken up by anaerobic microorganisms and reduced to reactive nitro radicals. These radicals damage DNA and inhibit nucleic acid synthesis, leading to cell death in susceptible bacteria and protozoa while sparing aerobic cells.

The dosage and duration of Metronidazol Vioser are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. No fixed regimen is provided here.

Metronidazol Vioser is classified as Pregnancy Category B, indicating no evidence of risk in animal studies but limited human data. It may be used during pregnancy only if the potential benefit justifies the risk. Caution is advised during breastfeeding, and the prescriber should evaluate infant exposure.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Metronidazol Vioser shares the same class mechanism as tinidazole and ornidazole but differs in pharmacokinetics. Metronidazole has a shorter half‑life, requiring more frequent dosing, while tinidazole offers a longer half‑life and may be dosed less often. Choice depends on infection type, patient tolerance, and prescriber preference.

Store Metronidazol Vioser at ambient temperature, below 25 °C, in its original packaging. Protect the solution from light, moisture, and extreme temperatures. Do not freeze. Follow standard aseptic handling procedures for intravenous products.

Metronidazol Vioser is administered intravenously by a qualified healthcare professional. It is typically diluted in compatible IV fluids and infused over a prescribed period, according to the prescriber's instructions and institutional protocols.

Serious risks include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, and rare skin conditions like Stevens‑Johnson syndrome. Patients should be monitored for neurological symptoms, rash, or signs of hypersensitivity, and therapy should be discontinued if severe reactions occur.

Metronidazol Vioser is contraindicated in patients with known hypersensitivity to metronidazole or other nitroimidazoles. It should also be avoided in individuals with a history of severe reactions to the drug, and caution is required in patients with significant hepatic or renal impairment unless dose adjustments are made.